| TOTAL (n = 78) | LBMD (n = 55) | NBMD (n = 23) | P§ |
---|---|---|---|---|
Demographic characteristics | Â | Â | Â | Â |
male | 68% | 66.7% | 69.6% | 0.80* |
mean age (IC 95%) | 46 (43–48) | 46 (43–48) | 45 (40–50) | 0.81 |
mean BMI (IC 95%) | 23.4 (22.5-24.3) | 23.4 (22.5-24.9) | 24.6 (23.0-26.2) | 0.16 |
HIV-related parameters | Â | Â | Â | Â |
AIDS diagnosis | 22% | 23% | 17% | 0.54* |
time from HIV diagnosis (IC 95%) | 7.8 years (6.3-9.3) | 7.8 years (5.8-9.8) | 7.8 years (5.5-10.4) | 0.99 |
mean CD4 nadir (IC 95%) | 268 cell/mm3 (226–310) | 266 cell/mm3 (214–317) | 265 cell/mm3 (195–336) | 0.98 |
mean current CD4 (IC 95%) | 507 cell/mm3 (437–577) | 490 cell/mm3 (400–579) | 512 cell/mm3 (407–617) | 0.77 |
mean CD4/CD8 ratio (IC 95%) | 0.7 (0.59-0.80) | 0.7 (0.54-0.77) | 0.8 (0.56-1.02) | 0.25 |
co-infection with viral hepatitis | Â | Â | Â | Â |
HCV Ab positivity | 10% | 12% | 4% | 0.26** |
HBsAg positivity | 5% | 3% | 8% | 0.63** |
naĂŻve patients | 26% | 28% | 17% | 0.31** |
mean time of HAART exposure (IC 95%) | 4.6 years (3.4-5.9) | 4.0 years (2.6-5.5) | 6.2 years (3.8-8.7) | 0.13 |
type of HAART | Â | Â | Â | 0.40* |
TDF-based backbone | 53% | 54% | 53% | Â |
PI-based | 33% | 34% | 35% | Â |
NNRTI-based | 37% | 33% | 48% | Â |
undetectable viremia (HIV-RNA <40 UI/mL) (in patients on HAART) | 92% | 88% | 94% | 1.00* |